PTC Therapeutics Inc
PTCT52.388USD
+0.258+0.49%
Horário de mercado （ET）Cotações atrasadas em 15 min
4.15BValor de mercado
6.98P/L TTM
Mais detalhes de PTC Therapeutics Inc Empresa
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company has a diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
Informações da empresa
Código da empresaPTCT
Nome da EmpresaPTC Therapeutics Inc
Data de listagemJun 20, 2013
CEODr. Matthew B. Klein, M.D.
Número de funcionários939
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 20
Endereço500 Warren Corporate Center Drive
CidadeWARREN
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal07059
Telefone19082227000
Sitehttps://www.ptcbio.com/
Código da empresaPTCT
Data de listagemJun 20, 2013
CEODr. Matthew B. Klein, M.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Michael Schmertzler
Mr. Michael Schmertzler
Independent Chairman of the Board
Independent Chairman of the Board
126.60K
+0.53%
Dr. Matthew B. Klein, M.D.
Dr. Matthew B. Klein, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
87.68K
-13.92%
Mr. Mark Elliott Boulding
Mr. Mark Elliott Boulding
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
60.20K
--
Ms. Christine Marie Utter
Ms. Christine Marie Utter
Senior Vice President, Chief Accounting Officer, Head - People Services
Senior Vice President, Chief Accounting Officer, Head - People Services
54.45K
-3.13%
Mr. Eric Pauwels
Mr. Eric Pauwels
Chief Business Officer
Chief Business Officer
19.79K
-16.96%
Mr. Pierre Gravier
Mr. Pierre Gravier
Chief Financial Officer
Chief Financial Officer
18.36K
-12.05%
Mr. David P. Southwell
Mr. David P. Southwell
Independent Director
Independent Director
16.17K
+13.98%
Dr. Jerome B. Zeldis, M.D., Ph.D.
Dr. Jerome B. Zeldis, M.D., Ph.D.
Independent Director
Independent Director
16.17K
+2.10%
Ms. Emma Reeve
Ms. Emma Reeve
Independent Director
Independent Director
12.87K
+2.66%
Ms. Stephanie S. Okey
Ms. Stephanie S. Okey
Independent Director
Independent Director
6.53K
+5.37%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Michael Schmertzler
Mr. Michael Schmertzler
Independent Chairman of the Board
Independent Chairman of the Board
126.60K
+0.53%
Dr. Matthew B. Klein, M.D.
Dr. Matthew B. Klein, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
87.68K
-13.92%
Mr. Mark Elliott Boulding
Mr. Mark Elliott Boulding
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
60.20K
--
Ms. Christine Marie Utter
Ms. Christine Marie Utter
Senior Vice President, Chief Accounting Officer, Head - People Services
Senior Vice President, Chief Accounting Officer, Head - People Services
54.45K
-3.13%
Mr. Eric Pauwels
Mr. Eric Pauwels
Chief Business Officer
Chief Business Officer
19.79K
-16.96%
Mr. Pierre Gravier
Mr. Pierre Gravier
Chief Financial Officer
Chief Financial Officer
18.36K
-12.05%
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
413.04M
51.20%
Non-US
393.74M
48.80%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sex, 16 de mai
Atualizado em: sex, 16 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
10.84%
RTW Investments L.P.
9.44%
BlackRock Institutional Trust Company, N.A.
7.50%
Armistice Capital LLC
6.86%
Wellington Management Company, LLP
6.84%
Other
58.52%
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
10.84%
RTW Investments L.P.
9.44%
BlackRock Institutional Trust Company, N.A.
7.50%
Armistice Capital LLC
6.86%
Wellington Management Company, LLP
6.84%
Other
58.52%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
40.10%
Investment Advisor
34.56%
Hedge Fund
20.09%
Research Firm
5.93%
Corporation
1.75%
Venture Capital
0.78%
Pension Fund
0.74%
Individual Investor
0.71%
Bank and Trust
0.31%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
542
83.25M
105.04%
-7.03M
2025Q1
551
82.28M
103.88%
-8.58M
2024Q4
513
80.63M
102.26%
-7.88M
2024Q3
503
82.04M
106.59%
-9.34M
2024Q2
498
82.97M
107.86%
-13.36M
2024Q1
493
89.17M
116.42%
-6.48M
2023Q4
485
88.17M
116.52%
-2.91M
2023Q3
477
85.04M
112.75%
-2.96M
2023Q2
478
84.63M
112.42%
-161.84K
2023Q1
486
82.00M
110.89%
-2.44M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
8.59M
10.84%
-571.45K
-6.24%
Mar 31, 2025
RTW Investments L.P.
7.48M
9.44%
+90.00K
+1.22%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
5.95M
7.5%
-111.10K
-1.83%
Mar 31, 2025
Armistice Capital LLC
5.43M
6.86%
-943.16K
-14.79%
Mar 31, 2025
Wellington Management Company, LLP
5.42M
6.84%
+632.05K
+13.20%
Mar 31, 2025
Janus Henderson Investors
2.92M
3.68%
+590.81K
+25.40%
Mar 31, 2025
TD Securities, Inc.
2.61M
3.3%
-673.53K
-20.49%
Mar 31, 2025
State Street Global Advisors (US)
2.45M
3.1%
-253.10K
-9.35%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.87M
2.36%
+76.87K
+4.28%
Mar 31, 2025
Driehaus Capital Management, LLC
1.51M
1.91%
+471.59K
+45.30%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
iShares Neuroscience and Healthcare ETF
4.12%
Invesco Biotechnology & Genome ETF
2.71%
ALPS Medical Breakthroughs ETF
2.62%
Virtus LifeSci Biotech Products ETF
1.85%
Harbor Human Capital Factor US Small Cap ETF
1.71%
Tema Neuroscience and Mental Health ETF
1.56%
Invesco Dorsey Wright Healthcare Momentum ETF
1.38%
Global X Guru Index ETF
1.29%
SPDR S&P Biotech ETF
1.21%
VictoryShares Small Cap Free Cash Flow ETF
0.88%
Ver Mais
iShares Neuroscience and Healthcare ETF
Proporção4.12%
Invesco Biotechnology & Genome ETF
Proporção2.71%
ALPS Medical Breakthroughs ETF
Proporção2.62%
Virtus LifeSci Biotech Products ETF
Proporção1.85%
Harbor Human Capital Factor US Small Cap ETF
Proporção1.71%
Tema Neuroscience and Mental Health ETF
Proporção1.56%
Invesco Dorsey Wright Healthcare Momentum ETF
Proporção1.38%
Global X Guru Index ETF
Proporção1.29%
SPDR S&P Biotech ETF
Proporção1.21%
VictoryShares Small Cap Free Cash Flow ETF
Proporção0.88%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
